Author

Kim Vanderliek

Miltenyi Biotec (Germany)

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Research Focus:clustering· 1 Approach:deep learning· 1

Frequent Co-Authors

Camille DourlensiD· 2 shared Daniel SchaeferiD· 2 shared Olaf HardtiD· 2 shared André Felsberger· 1 shared Helene Hubrich· 1 shared Jana Winkler· 1 shared Lilli Geiger· 1 shared Miriam DrosteiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

Camille DourlensORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Combinatorial adapter targeting enables AND-gate activation of AdCAR T cells in pancreatic cancer but reveals donor-dependent activation thresholds

Camille Dourlens, Kim Vanderliek, Olaf Hardt, Daniel Schaefer

This study shows that combinatorial adapter targeting in AdCAR T cells can selectively kill pancreatic cancer cells while avoiding off-tumor toxicity, but activation thresholds vary between donors.

bioRxiv · Jul 9, 2026 · PreprintImmunology

Engineering Functional CLA-Targeting CAR Approaches for Pancreatic Ductal Adenocarcinoma

Camille Dourlens, Kim Vanderliek, Lilli Geiger, Nico B. Burzan, Stefan Tomiuk, Miriam Droste, André Felsberger, Helene Hubrich, Jana Winkler, Olaf Hardt, Daniel Schaefer

This study develops functional CLA-targeting CAR approaches for pancreatic ductal adenocarcinoma by addressing limitations in CAR activity through genetic modification, affinity optimization, and novel AdCAR strategies.

bioRxiv · Jul 9, 2026 · PreprintImmunology